Compare WKHS & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKHS | CODX |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4M | 15.6M |
| IPO Year | N/A | 2017 |
| Metric | WKHS | CODX |
|---|---|---|
| Price | $6.54 | $0.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $21.00 | $2.25 |
| AVG Volume (30 Days) | 529.0K | ★ 1.7M |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,620,296.00 | $507,892.00 |
| Revenue This Year | $92.70 | N/A |
| Revenue Next Year | $34.00 | $18.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.73 | N/A |
| 52 Week Low | $6.30 | $0.23 |
| 52 Week High | $168.00 | $1.55 |
| Indicator | WKHS | CODX |
|---|---|---|
| Relative Strength Index (RSI) | 81.87 | 48.59 |
| Support Level | $6.30 | $0.34 |
| Resistance Level | $11.80 | $0.41 |
| Average True Range (ATR) | 0.60 | 0.04 |
| MACD | 0.72 | 0.00 |
| Stochastic Oscillator | 52.51 | 42.96 |
Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric delivery trucks and drone systems, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.